{
  "id": 12795321,
  "title": "Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older",
  "url": "https://urgent.news/2026/10/08/fall-clinical-2026-galderma-presents-new-three-year-nemluvio-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T05:00:23.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/fall-clinical-2026-galderma-presents-new-three-year-nemluvio-data-showing-deep-and-lasting-skin-lesion-and-itch-responses-in-patients-with-atopic-dermatitis-aged-12-and-older"
  },
  "original_language": "en",
  "account": null,
  "summary": "New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1 Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}